F16.28 Hallucinogen dependence with other hallucinogen-induced disorder

Name of the Condition

• Hallucinogen Dependence with Other Hallucinogen-Induced Disorder
• Medical Term: ICD-10-CM F16.28

Summary

Hallucinogen dependence with other hallucinogen-induced disorder is a medical condition characterized by a persistent pattern of hallucinogen use leading to clinically significant impairment or distress, accompanied by an additional hallucinogen-induced disorder. This may include symptoms such as perceptual disturbances, mood changes, or cognitive impairment directly resulting from hallucinogen use. The condition involves a compulsive need to use substances like LSD, psilocybin, or mescaline, despite negative consequences, and may involve tolerance, withdrawal, or an inability to control use.

Causes

Hallucinogen dependence typically develops from repeated or prolonged use of hallucinogenic substances. Psychological factors, such as pre-existing mental health conditions, and environmental influences, like social or peer pressure, may contribute to its onset. The drugs' mind-altering effects can reinforce continued use. The co-occurring hallucinogen-induced disorder arises directly from the pharmacological effects of the substance, such as perceptual distortions or mood alterations.

Risk Factors

• History of substance use disorders
• Pre-existing mental health conditions
• Young age, particularly adolescence or young adulthood
• Access to hallucinogenic substances
• Social or peer groups that normalize drug use

Symptoms

• Persistent craving for hallucinogens
• Inability to reduce or control use despite negative effects
• Tolerance, requiring increased amounts for the same effect
• Withdrawal symptoms when use is reduced or stopped
• Neglect of personal or professional responsibilities due to use
• Additional hallucinogen-induced symptoms (e.g., perceptual disturbances, mood changes)

Diagnosis

Diagnosis is based on a clinical evaluation that includes a detailed history of substance use, assessment of symptoms, and ruling out other medical or psychiatric conditions. Criteria from diagnostic manuals (e.g., DSM-5) are used to confirm dependence and identify the specific hallucinogen-induced disorder. Laboratory tests may be performed to exclude other causes, and collateral information from family or friends may be considered.

Treatment Options

Treatment typically involves a combination of behavioral therapies, such as cognitive-behavioral therapy (CBT) or motivational interviewing, to address dependence and co-occurring disorders. Medications may be used to manage withdrawal symptoms or underlying mental health conditions. Support groups and long-term follow-up care are often recommended to support recovery and prevent relapse.

Prognosis and Follow-Up

Prognosis varies depending on the severity of dependence, presence of co-occurring disorders, and response to treatment. Early intervention and consistent follow-up improve outcomes. Relapse is common, and ongoing monitoring is necessary to address recurrence of symptoms or dependence. Long-term management may include periodic assessments and adjustments to treatment plans.

Complications

• Worsening of co-occurring mental health conditions
• Increased risk of accidents or injuries due to impaired judgment
• Social or occupational dysfunction
• Financial or legal problems related to substance use
• Potential for overdose or adverse reactions to hallucinogens

Lifestyle & Prevention

• Avoiding exposure to hallucinogenic substances
• Building a strong support network of family and friends
• Engaging in healthy coping mechanisms for stress
• Participating in educational programs about substance use risks
• Seeking help early if substance use becomes problematic

When to Seek Professional Help

Seek professional help if you experience persistent cravings, loss of control over use, negative impacts on daily life, or symptoms of a hallucinogen-induced disorder. Early intervention can improve outcomes and reduce the risk of complications.

Tips for Medical Coders

When coding F16.28, ensure documentation clearly supports both hallucinogen dependence and the presence of another hallucinogen-induced disorder (e.g., perceptual disturbances, mood changes). The code requires specific evidence of the co-occurring disorder, which should be documented separately or linked to the dependence diagnosis. Verify that the substance use pattern meets criteria for dependence, including tolerance, withdrawal, or compulsive use, and that the induced disorder is directly attributable to hallucinogen use.